Markus from Portugal

Registered at the short selling broker Skilling, 5 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

GlaxoSmithKline Plc (GSK) shares information

GlaxoSmithKline Plc

24h Change

0.57 %


Live rate: Market closed

Stock data per Friday 23 Oct, 2020

New York Stock Exchange
0.2 (+ 0.57%)
US Market is closed

Live Stock price in graph for GlaxoSmithKline Plc (GSK)

  • Latest Volume

    5,153,774 (-25.35 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change


Quick links

Broker recommendations for GlaxoSmithKline Plc

The GlaxoSmithKline Plc stock is rated at 1.630435 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Wednesday 14 October, 2020 by a total of 23 brokers. This means that the consensus of the 23 different brokers is leaning toward to moderate buy/hold.

3 (13.04%)
0 (0%)
8 (34.78%)
1 (4.35%)
11 (47.83%)

Price target by analysts

The 18 latest analyst estimates, per Thursday 22 October, 2020, show the following high, low and average price targets.
Target Average: 47.94 USD
Target High: 60.41 USD
Target Low: 40.17 USD


Latest news about GlaxoSmithKline Plc

Below you can find the most recent news posts about GlaxoSmithKline Plc, primarily from US and UK based news sources.

GlaxoSmithKline (GSK) to Release Earnings on Wednesday

Saturday, 24 October 2020, 09:50:49
GlaxoSmithKline (NYSE:GSK) will be posting its quarterly earnings results before the market opens on Wednesday, October 28th. Analysts expect GlaxoSmithKline to post earnings of $0.78 per share for the quarter. GlaxoSmithKline has set its FY 2020 Pre-Market guidance at 1.56-1.60 EPS. GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, July 29th. The pharmaceutical company […]
— US Banking News

To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Competitors

Saturday, 24 October 2020, 06:00:00
The hunt for a solution to Covid-19 is producing an unlikely team of rivals in the cutthroat world of pharmaceuticals
— The Wall Street Journal

GlaxoSmithKline (NYSE:GSK) Stock Rating Reaffirmed by JPMorgan Chase & Co.

Friday, 23 October 2020, 03:32:41
GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating restated by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Wednesday, Borsen Zeitung reports. A number of other brokerages have also recently commented on GSK. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Monday, October […]
— The Lincolnian

GlaxoSmithKline PLC Holding(s) in Company

Thursday, 22 October 2020, 13:34:00
GlaxoSmithKline PLC 22 October 2020 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent…

Drug Repurposing Market Expected to Deliver Dynamic Progression until 2026 | Major Players GlaxoSmithKline, Atomwise, Biovista, Inc., Centene Corporation, NuMedii

Thursday, 22 October 2020, 12:27:03
The global drug repurposing market experiences growth due to shorter drug development time for repurposed drugs compared to new chemical entities. In addition, advances in the computational power to process large databases has allowed cost-effective solutions to approach drug development.
— OpenPR

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €/$ 20
Description: offer a large number of stocks for trading. Register an account today and check if they have GSK available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.